Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients

[1] Colleoni M(2009)Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting Breast. 18 137-40

[2] Viale G(1982)Tamoxifen as initial sole treatment of localized breast cancer in elderly women: a pilot study BMJ 284 869-870

[3] Goldhirsch A(1994)Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer Eur J Surg Oncol 20 207-214

[4] Preece PE(1994)Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G.R.E.T.A. Trial. Group for Research on Endocrine Therapy in the Elderly Anticancer Res 14 2197-200

[5] Wood RA(1992)Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up Eur J Cancer 28A 908-910

[6] Mackie CR(2001)Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2 positive, estrogen receptor positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 3808-3816

[7] Cuschieri A(2005)Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial J Clin Oncol 23 5108-5116

[8] Gazet JC(2006)Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer Cancer 106 2095-2103

[9] Ford HT(2007)Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer Cancer 110 244-254

[10] Coombes RC(2007)Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients Br J Cancer 96 1504-13

[1] Colleoni M(2009)Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting Breast. 18 137-40

[2] Viale G(1982)Tamoxifen as initial sole treatment of localized breast cancer in elderly women: a pilot study BMJ 284 869-870

[3] Goldhirsch A(1994)Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer Eur J Surg Oncol 20 207-214

[4] Preece PE(1994)Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G.R.E.T.A. Trial. Group for Research on Endocrine Therapy in the Elderly Anticancer Res 14 2197-200

[5] Wood RA(1992)Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up Eur J Cancer 28A 908-910

[6] Mackie CR(2001)Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2 positive, estrogen receptor positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 3808-3816

[7] Cuschieri A(2005)Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial J Clin Oncol 23 5108-5116

[8] Gazet JC(2006)Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer Cancer 106 2095-2103

[9] Ford HT(2007)Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer Cancer 110 244-254

[10] Coombes RC(2007)Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients Br J Cancer 96 1504-13